Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study - CALGB 9534

Wallace Akerley, James E. Herndon, Alan P. Lyss, Hak Choy, Andrew Turrisi, Stephen Graziano, Todd Williams, Chunfeng Zhang, Everett E. Vokes, Mark R. Green

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: This phase II cooperative group study of patiens with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with the same chemotherapy plus thoracic irradiation to 66 Gy. Patients and methods: All enrolled patients were scheduled to receive 2 cycles of induction PC at conventional doses. All nonprogressing patients were subsequently treated with concurrent chemoradiation, including 7 weekly doses of PC and once-daily thoracic irradiation. The eligibility criteria allowed treatment of an expanded population of patients, unrestricted by previous weight loss. Results: Despite the fact that 22% of patients had experienced > 5% weight loss in the preceding 6 months, 23 of the 40 eligible patients (58%) responded to the overall regimen. A 3-year failure-free survival rate of 15% and a 3-year overall survival rate of 27% were achieved. The 3-year overall survival rate is consistent with landmark cooperative group results for the combined modality treatment of a more highly selected patient population. Conclusion: The feasibility of this therapeutic approach in a cooperative group setting and inclusive of patients who were representative of the general population of stage III lung cancer patients was established.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalClinical Lung Cancer
Volume7
Issue number1
StatePublished - Jul 2005

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Therapeutics
Survival Rate
Weight Loss
Thorax
Population
Drug Therapy
Induction Chemotherapy
Lung Neoplasms

Keywords

  • Bronchogenic carcinoma
  • Combined-modality therapy
  • Thoracic radiation
  • Weight loss

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer : A limited-access study - CALGB 9534. / Akerley, Wallace; Herndon, James E.; Lyss, Alan P.; Choy, Hak; Turrisi, Andrew; Graziano, Stephen; Williams, Todd; Zhang, Chunfeng; Vokes, Everett E.; Green, Mark R.

In: Clinical Lung Cancer, Vol. 7, No. 1, 07.2005, p. 47-53.

Research output: Contribution to journalArticle

Akerley, W, Herndon, JE, Lyss, AP, Choy, H, Turrisi, A, Graziano, S, Williams, T, Zhang, C, Vokes, EE & Green, MR 2005, 'Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study - CALGB 9534', Clinical Lung Cancer, vol. 7, no. 1, pp. 47-53.
Akerley, Wallace ; Herndon, James E. ; Lyss, Alan P. ; Choy, Hak ; Turrisi, Andrew ; Graziano, Stephen ; Williams, Todd ; Zhang, Chunfeng ; Vokes, Everett E. ; Green, Mark R. / Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer : A limited-access study - CALGB 9534. In: Clinical Lung Cancer. 2005 ; Vol. 7, No. 1. pp. 47-53.
@article{d9d5a19f4da54c0588517e047fa42900,
title = "Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: A limited-access study - CALGB 9534",
abstract = "Background: This phase II cooperative group study of patiens with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with the same chemotherapy plus thoracic irradiation to 66 Gy. Patients and methods: All enrolled patients were scheduled to receive 2 cycles of induction PC at conventional doses. All nonprogressing patients were subsequently treated with concurrent chemoradiation, including 7 weekly doses of PC and once-daily thoracic irradiation. The eligibility criteria allowed treatment of an expanded population of patients, unrestricted by previous weight loss. Results: Despite the fact that 22{\%} of patients had experienced > 5{\%} weight loss in the preceding 6 months, 23 of the 40 eligible patients (58{\%}) responded to the overall regimen. A 3-year failure-free survival rate of 15{\%} and a 3-year overall survival rate of 27{\%} were achieved. The 3-year overall survival rate is consistent with landmark cooperative group results for the combined modality treatment of a more highly selected patient population. Conclusion: The feasibility of this therapeutic approach in a cooperative group setting and inclusive of patients who were representative of the general population of stage III lung cancer patients was established.",
keywords = "Bronchogenic carcinoma, Combined-modality therapy, Thoracic radiation, Weight loss",
author = "Wallace Akerley and Herndon, {James E.} and Lyss, {Alan P.} and Hak Choy and Andrew Turrisi and Stephen Graziano and Todd Williams and Chunfeng Zhang and Vokes, {Everett E.} and Green, {Mark R.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "7",
pages = "47--53",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer

T2 - A limited-access study - CALGB 9534

AU - Akerley, Wallace

AU - Herndon, James E.

AU - Lyss, Alan P.

AU - Choy, Hak

AU - Turrisi, Andrew

AU - Graziano, Stephen

AU - Williams, Todd

AU - Zhang, Chunfeng

AU - Vokes, Everett E.

AU - Green, Mark R.

PY - 2005/7

Y1 - 2005/7

N2 - Background: This phase II cooperative group study of patiens with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with the same chemotherapy plus thoracic irradiation to 66 Gy. Patients and methods: All enrolled patients were scheduled to receive 2 cycles of induction PC at conventional doses. All nonprogressing patients were subsequently treated with concurrent chemoradiation, including 7 weekly doses of PC and once-daily thoracic irradiation. The eligibility criteria allowed treatment of an expanded population of patients, unrestricted by previous weight loss. Results: Despite the fact that 22% of patients had experienced > 5% weight loss in the preceding 6 months, 23 of the 40 eligible patients (58%) responded to the overall regimen. A 3-year failure-free survival rate of 15% and a 3-year overall survival rate of 27% were achieved. The 3-year overall survival rate is consistent with landmark cooperative group results for the combined modality treatment of a more highly selected patient population. Conclusion: The feasibility of this therapeutic approach in a cooperative group setting and inclusive of patients who were representative of the general population of stage III lung cancer patients was established.

AB - Background: This phase II cooperative group study of patiens with unresectable stage III non-small-cell lung cancer was designed to treat patients with induction chemotherapy with paclitaxel and carboplatin (PC) followed by concurrent chemotherapy with the same chemotherapy plus thoracic irradiation to 66 Gy. Patients and methods: All enrolled patients were scheduled to receive 2 cycles of induction PC at conventional doses. All nonprogressing patients were subsequently treated with concurrent chemoradiation, including 7 weekly doses of PC and once-daily thoracic irradiation. The eligibility criteria allowed treatment of an expanded population of patients, unrestricted by previous weight loss. Results: Despite the fact that 22% of patients had experienced > 5% weight loss in the preceding 6 months, 23 of the 40 eligible patients (58%) responded to the overall regimen. A 3-year failure-free survival rate of 15% and a 3-year overall survival rate of 27% were achieved. The 3-year overall survival rate is consistent with landmark cooperative group results for the combined modality treatment of a more highly selected patient population. Conclusion: The feasibility of this therapeutic approach in a cooperative group setting and inclusive of patients who were representative of the general population of stage III lung cancer patients was established.

KW - Bronchogenic carcinoma

KW - Combined-modality therapy

KW - Thoracic radiation

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=23844557222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844557222&partnerID=8YFLogxK

M3 - Article

C2 - 16098244

AN - SCOPUS:23844557222

VL - 7

SP - 47

EP - 53

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -